Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire) - May 13, 2024 - "Luveltamab Tazevibulin (luvelta), FolRα-Targeting ADC Franchise:...An Investigational New Drug (IND) application for the treatment of NSCLC has been cleared by U.S. Food and Drug Administration (FDA). The Phase 2 trial is expected to begin enrolling patients in the second half of 2024. Initial data is expected in the first half of 2025."
IND • New P2 trial • Non Small Cell Lung Cancer
|